Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept

Radiographic efficacy of adalimumab in patients with psoriatic arthritis according to demographics, baseline clinical status, methotrexate use and clinical response: subanalysis of adept

Bibliográfalaš dieđut
Váldodahkkit:	Choy, E, Gladman, D, Mease, P, Wordsworth, P, Ritchlin, C, Wang, H, Sasso, E
Materiálatiipa:	Conference item
Almmustuhtton:	2007

Geahča maid

Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept
Dahkki: Kavanaugh, A, et al.
Almmustuhtton: (2005)

Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity
Dahkki: Landewé, R, et al.
Almmustuhtton: (2019)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
Dahkki: Mease, P, et al.
Almmustuhtton: (2017)

Methotrexate in psoriasis and psoriatic arthritis
Dahkki: Coates, L, et al.
Almmustuhtton: (2020)

Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study
Dahkki: Elden Aake, et al.
Almmustuhtton: (2011-02-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
Dahkki: Gladman, DD, et al.
Almmustuhtton: (2022)

A randomized, phase 3, double-blind trial examining methotrexate and etanercept as monotherapy or in combinstion for treating psoriatic arthritis: A comparison of the composite measures used to evaluate disease activity
Dahkki: Mease, PJ, et al.
Almmustuhtton: (2019)

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
Dahkki: Mease, P, et al.
Almmustuhtton: (2018)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
Dahkki: Dafna D. Gladman, et al.
Almmustuhtton: (2022-02-01)

Adalimumab in treatment of psoriatic arthritis
Dahkki: V. V. Badokin
Almmustuhtton: (2008-08-01)

Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis
Dahkki: V. V. Didenko, et al.
Almmustuhtton: (2021-05-01)

Use of the interleukin-17A inhibitor secukinumab in psoriatic arthritis: a subanalysis of the Russian population in the international randomized clinical trials FUTURE 1 and FUTURE 2
Dahkki: T. V. Korotaeva, et al.
Almmustuhtton: (2017-04-01)

Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study
Dahkki: Coates, LC, et al.
Almmustuhtton: (2022)

An ADEPT apology reply
Dahkki: Pandit, J, et al.
Almmustuhtton: (2012)

Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis
Dahkki: Philip Mease, et al.
Almmustuhtton: (2022-12-01)

Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis
Dahkki: E. Yu. Loginova, et al.
Almmustuhtton: (2021-06-01)

Comparative characteristics of early psoriatic arthritis with and without axial skeleton injury (a subanalysis of the all-Russian registry of patients with psoriatic arthritis)
Dahkki: E. E. Gubar, et al.
Almmustuhtton: (2019-12-01)

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Dahkki: Alison O’Mahony, et al.
Almmustuhtton: (2018-06-01)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
Dahkki: Coates, L, et al.
Almmustuhtton: (2020)

THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS
Dahkki: Elena Yurievna Loginova, et al.
Almmustuhtton: (2010-06-01)

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
Dahkki: Tillett, W, et al.
Almmustuhtton: (2017)

The association between sonographic enthesitis and radiographic damage in psoriatic arthritis
Dahkki: Ari Polachek, et al.
Almmustuhtton: (2017-08-01)

Methotrexate in a psoriatic arthritis patient
Dahkki: K. V. Aleksanyan, et al.
Almmustuhtton: (2022-12-01)

Evaluation of Clinical and Ultrasonographic Parameters in Psoriatic Arthritis Patients Treated with Adalimumab: A Retrospective Study
Dahkki: M. Teoli, et al.
Almmustuhtton: (2012-01-01)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
Dahkki: Nash, P, et al.
Almmustuhtton: (2020)

CLINICAL AND RADIOGRAPHICAL CHARACTERISTICS OF MELORRHOESTOSIS
Dahkki: Chan, M, et al.
Almmustuhtton: (2009)

Adept : Ex Machina /
Dahkki: Finn, Robert
Almmustuhtton: (2006)

Correction to: The association between sonographic enthesitis and radiographic damage in psoriatic arthritis
Dahkki: Ari Polachek, et al.
Almmustuhtton: (2019-01-01)

Use of methotrexate in the treatment of psoriasis and psoriatic arthritis
Dahkki: Tatiana Viktorovna Korotaeva, et al.
Almmustuhtton: (2013-06-01)

Erosions of Psoriatic Plaques Due to Methotrexate
Dahkki: Leandro Silva, et al.
Almmustuhtton: (2021-06-01)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
Dahkki: Ogdie, A, et al.
Almmustuhtton: (2023)

Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis
Dahkki: Philip J Mease, et al.
Almmustuhtton: (2024-02-01)

Classification and outcome measures for psoriatic arthritis
Dahkki: Leung, Y, et al.
Almmustuhtton: (2018)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
Dahkki: Coates, L, et al.
Almmustuhtton: (2017)

Subanalysis of the AUGUSTUS trial
Dahkki: T. V. Pavlova, et al.
Almmustuhtton: (2020-09-01)

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled tria
Dahkki: Ritchlin, CT, et al.
Almmustuhtton: (2023)

Language competency, culturally adept
Dahkki: Sani, Rozana
Almmustuhtton: (2019)

Technically adept, intellectually capable
Dahkki: Rozana, Sani
Almmustuhtton: (2019)

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis
Dahkki: Dafna D. Gladman, et al.
Almmustuhtton: (2024-12-01)

Methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis
Dahkki: N. V. Chichasova, et al.
Almmustuhtton: (2021-06-01)